NBCD pharmacokinetics and bioanalytical methods to measure drug release

AAPS Advances in the Pharmaceutical Sciences Series

Volumn 20, Issue , 2015, Pages 261-287

  Ambardekar, Vishakha V ^a   Stern, Stephan T ^a  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

Bioanalytical methods; Drug release methods; Equilibrium dialysis; Liquid liquid extraction; Metabolite pharmacokinetics; Modeling and simulation; Nanomedicine; Non biological complex drugs; Pharmacokinetics; Size exclusion chromatography; Solid phase extraction; Ultracentrifugation; Ultrafiltration

Indexed keywords

DRUG; GENERIC DRUG; NON BIOLOGICAL COMPLEX DRUG; UNCLASSIFIED DRUG;

ARTICLE; BIOEQUIVALENCE; DRUG RELEASE; DRUG SOLUBILITY; EQUILIBRIUM DIALYSIS; GEL PERMEATION CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; NANOMEDICINE; PRIORITY JOURNAL; PROTEIN BINDING; SIMULATION; SOLID PHASE EXTRACTION; ULTRACENTRIFUGATION; ULTRAFILTRATION;

EID: 85065457811     PISSN: 22107371     EISSN: 2210738X     Source Type: Book Series    
DOI: 10.1007/978-3-319-16241-6_8     Document Type: Article

References (84)

1. Ahmad A, Wang YF, Ahmad I (2005) Separation of liposome-entrapped mitoxantrone from nonliposomal mitoxantrone in plasma: pharmacokinetics in mice. Methods Enzymol 391:176-185
2. Albanese A, Tang PS, Chan WC (2012) The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 14:1-16
3. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ (2002) Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 46:834-840
4. Bellott R, Pouna P, Robert J (2001) Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome. J Chromatogr B Biomed Sci Appl 757:257-267
5. Blanco E, Hsiao A, Mann AP, Landry MG, Meric-Bernstam F, Ferrari M (2011) Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci 102:1247-1252
6. Boyd BJ, Kaminskas LM, Karellas P, Krippner G, Lessene R, Porter CJ (2006) Cationic poly-Llysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats. Mol Pharm 3:614-627
7. Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ (2009) Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Cancer Chemother Pharmacol 63:1049-1063
8. Code of Federal Regulations (CFR) (2013, April) Content and format of an abbreviated application, 21 CFR 314.94. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch. cfm?fr=314.94. Accessed 24 April 2015
9. de Assis DN, Mosqueira VC, Vilela JM, Andrade MS, Cardoso VN (2008) Release profiles and morphological characterization by atomic force microscopy and photon correlation spectroscopy of 99mTechnetium-fluconazole nanocapsules. Int J Pharm 349:152-160
10. Decker C, Steiniger F, Fahr A (2013) Transfer of a lipophilic drug (temoporfin) between small unilamellar liposomes and human plasma proteins: influence of membrane composition on vesicle integrity and release characteristics. J Liposome Res 23:154-165
11. Desai N (2012) Challenges in development of nanoparticle-based therapeutics. AAPS J 14:282- 295
12. Deshpande NM, Gangrade MG, Kekare MB, Vaidya VV (2010) Determination of free and liposomal amphotericin B in human plasma by liquid chromatography-mass spectroscopy with solid phase extraction and protein precipitation techniques. J Chromatogr B Analyt Technol Biomed Life Sci 878:315-326
13. Druckmann S, Gabizon A, Barenholz Y (1989) Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies. Biochim Biophys Acta 980:381-384
14. Duncan R, Gaspar R (2011) Nanomedicine(s) under the microscope. Mol Pharm 8:2101-2141
15. Ehmann F, Sakai-Kato K, Duncan R, Hernan Perez de la Ossa D, Pita R, Vidal JM, Kohli A, Tothfalusi L, Sanh A, Tinton S, Robert JL, Silva Lima B, Amati MP (2013) Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. Nanomedicine (Lond) 8:849-856
16. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP) (2008) Draft, Guideline on the investigation of bioequivalence. http://www.ema.europa.eu/ docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003011.pdf. Accessed 24 April 2015
17. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP) (2011a) CHMP assessment report: doxorubicin sun. http://www.ema.europa.eu/ docs/en_GB/document_library/Application_withdrawal_assessment_report/human/002049/ WC500112957.pdf. Accessed 24 April 2015
18. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP) (2011b) Draft, Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product. http://www.ema.europa.eu/docs/en_ GB/document_library/Scientific_guideline/2011/07/WC500109479.pdf. Accessed 24 April 2015
19. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP) (2011c) Reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/ 2011/04/WC500105048.pdf. Accessed 24 April 2015
20. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP) (2013a) Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_ guideline/2013/02/WC500138390.pdf. Accessed 24 April 2015
21. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP) (2013b) Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product. http://www.ema.europa. eu/docs/en_GB/document_library/Scientific_guideline/2013/09/WC500149496.pdf. Accessed 24 April 2015 284 V. V. Ambardekar and S. T. Stern
22. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) (2000, August) Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. http://www.fda.gov/downloads/Drugs/Guidances/ucm070246.pdf. Accessed 24 April 2015
23. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) (2001, January) Statistical approaches to establishing bioeuivalence. http://www.fda.gov/downloads/ Drugs/Guidances/ucm070244.pdf. Accessed 24 April 2015
24. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) (2002, July) Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations. http://www.fda.gov/downloads/drugs/developmentapprovalprocess/ howdrugsaredevelopedandapproved/approvalapplications/abbreviatednewdrugapplicationandagenerics/ ucm154838.pdf. Accessed 24 April 2015
25. Food and Drug Administration (FDA), Office of Generic Drugs (2012a, March) Draft guidance on iron sucrose bioequivalence. http://www.fda.gov/downloads/Drugs/GuidanceCompliance- RegulatoryInformation/Guidances/UCM297630.pdf. Accessed 24 April 2015
26. Food and Drug Administration (FDA), Office of Generic Drugs (2012b, September) Draft guidance on paclitaxel. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm320015.pdf. Accessed 24 April 2015
27. Food and Drug Administration (FDA) (2012c, December) Draft guidance on ferumoxytol. http:// www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM333051.pdf. Accessed 24 April 2015
28. Food and Drug Administration (FDA) (2013a, February) FDA approval of generic version of cancer drug Doxil is expected to help resolve shortage. http://www.fda.gov/newsevents/newsroom/ pressannouncements/ucm337872.htm. Accessed 24 April 2015
29. Food and Drug Administration (FDA) (2013b, April) Therapeutic equivalence of generic iron complex products. (Solicitation for a study on Na ferric gluconate; Nulecit (followon upon 505j approval) vs Ferrlecit (originator)). www.fbo.gov/index?s=opportunity&mode=form&id =592788989854da145c8e7b6d103c898d&tab=core&tabmode=list&. Accessed 24 April 2015
30. Food and Drug Administration (FDA), Office of Generic Drugs (2013c, November) Draft guidance on doxorubicin hydrochloride. http://www.fda.gov/downloads/Drugs/…/Guidances/ UCM199635.pdf. Accessed 24 April 2015
31. Food and Drug Administration (FDA), Office of Generic Drugs (2014a, April) Draft guidance on amphotericin B. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM384094.pdf. Accessed 24 April 2015
32. Food and Drug Administration (FDA), Office of Generic Drugs (2014b, April) Draft guidance on verteporfin. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM384173.pdf. Accessed 24 April 2015
33. Food and Drug Administration (FDA) (2014c, July) Draft guidance on daunorubicin citrate. http:// www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM406256.pdf. Accessed 24 April 2015
34. Gabizon A, Martin F (1997) Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 54(Suppl 4):15-21
35. Gardner ER, Dahut W, Figg WD (2008a) Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment. J Chromatogr B Analyt Technol Biomed Life Sci 862:213-218
36. Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A, Figg WD (2008b) Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 14:4200-4205
37. Gillen CM, Takamata A, Mack GW, Nadel ER (1994) Measurement of plasma volume in rats with use of fluorescent-labeled albumin molecules. J Appl Physiol (1985) 76:485-489
38. Gómez-Hens A, Fernández-Romero JM (2006) Analytical methods for the control of liposomal delivery systems. TrAC Trends Anal Chem 25:167-178
39. Gregoriadis G (1991) Overview of liposomes. J Antimicrob Chemother 28(Suppl B):39-48
40. Hagel L (2001) Gel-filtration chromatography. Curr Protoc Protein Sci Chapter 8:Unit 8.3
41. He C, Hu Y, Yin L, Tang C, Yin C (2010) Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31:3657-3666
42. Jiang W, Kim BY, Rutka JT, Chan WC (2007) Advances and challenges of nanotechnology-based drug delivery systems. Expert Opin Drug Deliv 4:621-633
43. Jiang W, Lionberger R, Yu LX (2011) In vitro and in vivo characterizations of PEGylated liposomal doxorubicin. Bioanalysis 3:333-344
44. Kaiser N, Kimpfler A, Massing U, Burger AM, Fiebig HH, Brandl M, Schubert R (2003) 5-Fluorouracil in vesicular phospholipid gels for anticancer treatment: entrapment and release properties. Int J Pharm 256:123-131
45. Kaminskas LM, Boyd BJ, Karellas P, Krippner GY, Lessene R, Kelly B, Porter CJ (2008) The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers. Mol Pharm 5:449-463
46. Kole PL, Venkatesh G, Kotecha J, Sheshala R (2011) Recent advances in sample preparation techniques for effective bioanalytical methods. Biomed Chromatogr 25:199-217
47. Krishna R, Webb MS, St Onge G, Mayer LD (2001) Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther 298:1206-1212
48. Libutti SK, Paciotti GF, Byrnes AA, Alexander HR Jr, Gannon WE, Walker M, Seidel GD, Yuldasheva N, Tamarkin L (2010) Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 16:6139-6149
49. Maeda H (2012) Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci 88:53-71
50. Magin RL, Chan HC (1987) Rapid separation of liposomes using ultrafiltration. Biotechnol Tech 1:185-188
51. Mayer LD, St-Onge G (1995) Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques. Anal Biochem 232:149-157
52. Mayer LD, Cullis PR, Bally MB (1994) The use of transmembrane pH gradient-driven drug encapsulation in the pharmacodynamic evaluation of liposomal doxorubicin. J Liposome Res 4:529-553
53. Mei L, Zhang Z, Zhao L, Huang L, Yang XL, Tang J, Feng SS (2013) Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv Drug Deliv Rev 65:880-890
54. Onoue S, Yamada S, Chan HK (2014) Nanodrugs: pharmacokinetics and safety. Int J Nanomedicine 9:1025-1037
55. Owens DE 3rd, Peppas NA (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307:93-102
56. Prantner AM, Scholler N (2014) Biological barriers and current strategies for modifying nanoparticle bioavailability. J Nanosci Nanotechnol 14:115-125
57. Public Health Service (PHS) Act Sect. 351(k). http://www.fda.gov/regulatoryinformation/legislation/ ucm148717.htm. Accessed 24 April 2015
58. Reshetov V, Zorin V, Siupa A, D'Hallewin MA, Guillemin F, Bezdetnaya L (2012) Interaction of liposomal formulations of meta-tetra(hydroxyphenyl)chlorin (temoporfin) with serum proteins: protein binding and liposome destruction. Photochem Photobiol 88:1256-1264
59. Ricci M, Giovagnoli S, Blasi P, Schoubben A, Perioli L, Rossi C (2006) Development of liposomal capreomycin sulfate formulations: effects of formulation variables on peptide encapsulation. Int J Pharm 311:172-181
60. Singh JK, Solanki A, Maniyar RC, Banerjee D, Shirsath VS (2012) Rapid Equilibrium Dialysis (RED): an in-vitro high-throughput screening technique for plasma protein binding using human and rat plasma. J Bioequiv Bioavailab S14:1-4
61. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59:1454-1457
62. Stern ST, Hall JB, Yu LL, Wood LJ, Paciotti GF, Tamarkin L, Long SE, McNeil SE (2010) Translational considerations for cancer nanomedicine. J Control Release 146:164-174
63. Stern ST, Zou P, Skoczen S, Xie S, Liboiron B, Harasym T, Tardi P, Mayer LD, McNeil SE (2013) Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion. J Control Release 172:558-567
64. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A (2003) Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 42:665-685
65. Thies RL, Cowens DW, Cullis PR, Bally MB, Mayer LD (1990) Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma. Anal Biochem 188:65-71
66. Torchilin V (2011) Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63:131-135
67. United States Pharmacopeia (USP) (2011, December) Chapter U7117, Dissolution. http://www. usp.org/sites/default/files/usp_pdf/EN/USPNF/2011-02-25711DISSOLUTION.pdf. Accessed 24 April 2015
68. van Haandel L, Stobaugh JF (2010) Bioanalytical method development for a generation 5 polyamidoamine folic acid methotrexate conjugated nanoparticle. Anal Bioanal Chem 397:1841-1852
69. Vannucci L, Falvo E, Fornara M, Di Micco P, Benada O, Krizan J, Svoboda J, Hulikova-Capkova K, Morea V, Boffi A, Ceci P (2012) Selective targeting of melanoma by PEG-masked proteinbased multifunctional nanoparticles. Int J Nanomedicine 7:1489-1509
70. Vuignier K, Schappler J, Veuthey JL, Carrupt PA, Martel S (2010) Drug-protein binding: a critical review of analytical tools. Anal Bioanal Chem 398:53-66
71. Wallace SJ, Li J, Nation RL, Boyd BJ (2012) Drug release from nanomedicines: selection of appropriate encapsulation and release methodology. Drug Deliv Transl Res 2:284-292
72. Yamamoto E, Hyodo K, Ohnishi N, Suzuki T, Ishihara H, Kikuchi H, Asakawa N (2011) Direct, simultaneous measurement of liposome-encapsulated and released drugs in plasma by on-line SPE-SPE-HPLC. J Chromatogr B Analyt Technol Biomed Life Sci 879:3620-3625
73. Yang F, Wang H, Liu M, Hu P, Jiang J (2013) Determination of free and total vincristine in human plasma after intravenous administration of vincristine sulfate liposome injection using ultra-high performance liquid chromatography tandem mass spectrometry. J Chromatogr A 1275:61-69
74. Yasui K, Fujioka H, Nakamura Y (1995) Controlled release by Ca(2+)-sensitive recombinant human tumor necrosis factor-alpha liposomes. Chem Pharm Bull (Tokyo) 43:508-511
75. Zamboni WC, Strychor S, Joseph E, Walsh DR, Zamboni BA, Parise RA, Tonda ME, Yu NY, Engbers C, Eiseman JL (2007) Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts. Clin Cancer Res 13:7217-7223
76. Zamboni WC, Ramalingam S, Friedland DM, Edwards RP, Stoller RG, Strychor S, Maruca L, Zamboni BA, Belani CP, Ramanathan RK (2009a) Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clin Cancer Res 15:1466-1472
77. Zamboni WC, Strychor S, Maruca L, Ramalingam S, Zamboni BA, Wu H, Friedland DM, Edwards RP, Stoller RG, Belani CP, Ramanathan RK (2009b) Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. Clin Pharmacol Ther 86:519-526
78. Zamboni WC, Eiseman JL, Strychor S, Rice PM, Joseph E, Zamboni BA, Donnelly MK, Shurer J, Parise RA, Tonda ME, Yu NY, Basse PH (2011a) Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models. J Liposome Res 21:70-80
79. Zamboni WC, Maruca LJ, Strychor S, Zamboni BA, Ramalingam S, Edwards RP, Kim J, Bang Y, Lee H, Friedland DM, Stoller RG, Belani CP, Ramanathan RK (2011b) Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors. J Liposome Res 21:158-165
80. Zhang J, Li X, Huang L (2014) Non-viral nanocarriers for siRNA delivery in breast cancer. J Control Release 190:440-50
81. Zhao X, Mou D, Wan J, Xu H, Yang X (2009) A novel method for the separation and determination of non-encapsulated pyrene in plasma and its application in pharmacokinetic studies of pyreneloaded MPEG-PLA based nanoparticles. Nanotechnology 20:125701
82. Zolnik BS, Stern ST, Kaiser JM, Heakal Y, Clogston JD, Kester M, McNeil SE (2008) Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab Dispos 36:1709- 1715
83. Zou P, Helson L, Maitra A, Stern ST, McNeil SE (2013) Polymeric curcumin nanoparticle pharmacokinetics and metabolism in bile duct cannulated rats. Mol Pharm 10:1977-1987
84. Żwir-Ferenc A, Biziuk M (2006) Solid phase extraction technique-trends, opportunities and applications. Polish J Environ Stud 15:677-690